November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
1 citations
,
June 2022 in “JAMA” Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
May 2026 in “Indian Journal of Dermatology” Rituximab effectively managed a difficult case of juvenile lupus with complications, reducing the need for steroids.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
3 citations
,
October 2021 in “Brain Sciences” Long-term use of Risperidone may be linked to a serious skin condition in bipolar patients, affecting their overall well-being.
September 2023 in “Journal of the American Academy of Dermatology” Low-dose oral naltrexone may help reduce inflammation in some scarring alopecia patients.
9 citations
,
April 2021 in “Evidence-based complementary and alternative medicine” Guilu Erxian Glue may help reduce chemotherapy side effects like weight loss and heart stress.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
February 2026 in “Reports — Medical Cases Images and Videos” Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
3 citations
,
August 2023 in “Journal of Cutaneous Medicine and Surgery” Topical Flutamide 1% gel effectively and safely reduces acne.
31 citations
,
July 1975 in “PubMed” Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
January 2023 in “Journal of The American Academy of Dermatology” Being overweight, having gallbladder removal surgery, and taking cholesterol-lowering drugs are linked to a higher chance of getting vulvar lichen sclerosus.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
4 citations
,
December 2024 in “Clinical Cosmetic and Investigational Dermatology” Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.
1 citations
,
May 2021 in “Journal of the Endocrine Society” A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.
96 citations
,
December 2015 in “JAMA dermatology” Topical Ruxolitinib may safely treat severe hair loss.
January 2015 in “Annals of dermatology/Annals of Dermatology” Using travoprost for glaucoma may cause extra hair growth and darker skin around the eyes, but these effects can reverse after stopping the drug.
1 citations
,
July 2020 in “Journal of cosmetic dermatology” A woman on immunosuppressants developed two rare scalp conditions, which improved with specific treatments.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
May 2026 in “Acta Dermato Venereologica” Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.
May 2026 in “Dermatologic Surgery” GLP-1RAs may cause hair loss but could also help regrow hair in some cases.
April 2018 in “Journal of Investigative Dermatology” A new treatment using AGED to modulate PPAR-γ shows promise for treating scarring hair loss by protecting and repairing hair follicle cells.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
April 2024 in “Rheumatology” A young woman with visual issues and other symptoms was diagnosed with lupus and antiphospholipid syndrome, and improved with treatment.
2 citations
,
July 2007 in “Cancer biology & therapy” Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.